Publications by authors named "Astrid Slagter"
Background: Data on the clinicopathological characteristics of mucinous gastric cancer (muc-GC) are limited. This study compares the clinical outcome and response to chemotherapy between patients with resectable muc-GC, intestinal (int-GC), and diffuse (dif-GC) gastric cancer.
Methods: Patients from the D1/D2 study or the CRITICS trial were included in exploratory surgery-alone (SAtest) or chemotherapy test (CTtest) cohorts.
Article Synopsis
- The study examines how sex affects outcomes in patients with resectable gastric cancer, focusing on histological subtype differences.
- It analyzes data from the CRITICS-trial, comparing survival rates, toxicity, and compliance between male and female patients.
- Results show that females have higher rates of positive tumor margins in diffuse gastric cancer and experience more treatment-related toxicity, but this does not significantly impact their treatment effectiveness.
Article Synopsis
- Perioperative chemotherapy is the standard treatment for resectable gastric cancer, with oxaliplatin gaining preference over cisplatin, though evidence for its superiority is lacking.
- The CRITICS trial compared outcomes between patients using cisplatin (632) and oxaliplatin (149) and examined their effects on patient health and tumor response.
- While both drugs led to severe toxicity rates (67% for cisplatin vs. 60% for oxaliplatin), the overall survival and tumor response outcomes showed no significant differences, indicating both are viable treatment options.
Aim: To evaluate the prognostic value of tumor markers in a European cohort of patients with resectable gastric cancer.
Methods: We performed a post hoc analysis of the CRITICS trial, in which 788 patients received perioperative therapy. Association between survival and pretreatment CEA, CA 19-9, alkaline phosphatase, neutrophils, hemoglobin and lactate dehydrogenase were explored in uni- and multivariable Cox regression analyses.
Risk Factors for Metachronous Isolated Peritoneal Metastasis after Preoperative Chemotherapy and Potentially Curative Gastric Cancer Resection: Results from the CRITICS Trial.
Cancers (Basel)
September 2021
Gastric cancer (GC) patients at high risk of developing peritoneal metastasis (PM) as a single site of metastasis after curative treatment may be candidates for adjuvant prophylactic strategies. Here we investigated risk factors for metachronous isolated PM in patients who were treated in the CRITICS trial (NCT00407186). Univariable and multivariable analyses on both metachronous isolated PM and 'other events', i.
View Article and Find Full Text PDFGastric cancer is the fifth most common cancer worldwide and has a high mortality rate. In the last decades, treatment strategy has shifted from an exclusive surgical approach to a multidisciplinary strategy. Treatment options for patients with resectable gastric cancer as recommended by different worldwide guidelines, include perioperative chemotherapy, pre- or postoperative chemoradiotherapy and postoperative chemotherapy.
View Article and Find Full Text PDFBackground: The occurrence of a venous thromboembolism (VTE) is common in patients with cancer. Gastric cancer has been associated with one of the highest risks for VTE. Chemotherapy, especially cisplatin has been associated with a high VTE risk.
View Article and Find Full Text PDFArticle Synopsis
- The study aims to determine how the status and number of lymph node (LN) metastases impact relapse-free survival (RFS) and overall survival (OS) in patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs) post-surgery.
- Researchers analyzed data from 217 patients who underwent curative resection for GEP NETs between 2002 and 2017, excluding grade 3 tumors, to evaluate various survival factors.
- Key findings indicate that factors like perineural invasion, LN positivity, and retrieving 8 or more LNs are significantly associated with shorter RFS, while tumor necrosis also correlates with worsened survival outcomes.
Aim: To evaluate treatment-related toxicity, treatment compliance, surgical complications and event-free survival (EFS) in older (≥70 years) versus younger (<70 years) adults who underwent perioperative treatment for gastric cancer.
Methods: In the CRITICS trial, 788 patients with resectable gastric cancer were randomised before start of any treatment and received preoperative chemotherapy (3 cycles of epirubicin, cisplatin or oxaliplatin and capecitabine), followed by surgery, followed by either postoperative chemotherapy or chemoradiotherapy (45Gy + cisplatin + capecitabine).
Results: 172 (22%) patients were older adults.
Background: Sorafenib has demonstrated survival benefit in first-line treatment of advanced hepatocellular carcinoma (HCC); utility of sorafenib in patients with advanced HCC and Child-Pugh B (CP-B) liver function remains a subject of debate.
Methods: A systematic review identified studies using first-line sorafenib in patients with advanced HCC and CP-A/B liver function. Meta-regression analysis comprising linear regression was conducted to explore the association between the baseline factors and overall survival (OS).
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
BMC Cancer
September 2018
Background: Although radical surgery remains the cornerstone of cure in resectable gastric cancer, survival remains poor. Current evidence-based (neo)adjuvant strategies have shown to improve outcome, including perioperative chemotherapy, postoperative chemoradiotherapy and postoperative chemotherapy. However, these regimens suffer from poor patient compliance, particularly in the postoperative phase of treatment.
View Article and Find Full Text PDF